Since NICE was established in 1999, we’ve delivered vast amounts of guidance. More than many other health technology assessment bodies across the globe. But health and care has changed rapidly since ...

We are extremely disappointed that talks to reach a price agreement that would have made advanced breast cancer drug Enhertu available to around 1000 women in England and Wales have not been ...

Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806 Medicine Not selected 1 November 2024 Human normal ...

According to the study, technologies that received scientific advice took a median of 312 days to progress from marketing ...

These tools set cookies that store anonymised information about how you got to the site, and how you interact with the site.

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

Pembrolizumab (Keytruda, Merck Sharp and Dohme) 'in combination with platinum-containing chemotherapy, as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated ...

Pembrolizumab is recommended, within its marketing authorisation, as an option for neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for resectable ...

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...